Physician profile
Stephanie Pointer
NPI 1518300607
$7,622.40
in general payments reported to CMS, 2019-2025
42 companies · $3,834 in 2025
The $3,834 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,427 · 2023: $1,175 · 2024: $1,186 · 2025: $3,834.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,050 · Consulting Fee: $2,000 · Education: $146.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,049.58 |
| Consulting Fee | $2,000.00 |
| Education | $145.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $2,017.69 | 2022-2025 | |
| Abbvie INC. | $1,292.03 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $735.15 | 2022-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $680.46 | 2022-2025 | Tremfya, Stelara, Simponi |
| Gilead Sciences, INC. | $532.92 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $356.86 | 2023-2025 | Entyvio, Eohilia, Gattex |
| Merck Sharp & Dohme LLC | $188.50 | 2022-2024 | Dificid |
| Genzyme Corporation | $171.66 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $171.29 | 2024-2025 | Zenpep |
| Pfizer INC. | $154.93 | 2024-2025 | |
| Redhill Biopharma INC. | $136.16 | 2022-2025 | Talicia |
| Qol Medical, LLC | $127.14 | 2023-2025 | Sucraid |
| Lilly USA, LLC | $125.35 | 2024-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $103.95 | 2022-2023 | Dupixent |
| Ardelyx, INC. | $102.98 | 2024-2025 | Ibsrela |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $76.93 | 2023-2025 | Wegovy |
| Intercept Pharmaceuticals, INC. | $61.93 | 2022-2023 | Ocaliva |
| Boston Scientific Corporation | $60.98 | 2023-2025 | Therasphere Y90 Glass Microspheres 10 Gbq, Resolution Clip |
| Celgene Corporation | $55.86 | 2022-2024 | Zeposia |
| Braintree Laboratories, INC. | $45.53 | 2024 | Suflave |
| Fujifilm Healthcare Americas Corporation | $42.85 | 2024 | Utaswako Afp-L3 |
| Madrigal Pharmaceuticals | $39.33 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Pharmaceuticals, INC | $36.96 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $36.18 | 2025 | Iqirvo |
| Ironwood Pharmaceuticals, INC | $35.92 | 2022 | |
| Medtronic, INC. | $34.63 | 2023 | Interstim |
| Celltrion USA INC. | $30.64 | 2024-2025 | Vegzelma |
| Micro-Tech Endoscopy USA, INC. | $28.56 | 2024 | Lesionhunter, Dat |
| Lucid Diagnostics INC. | $25.10 | 2023 | |
| Ferring Pharmaceuticals INC. | $20.06 | 2023 | Rebyota |
| Endogastric Solutions, INC | $19.90 | 2023 | Esophyx |
| Organon LLC | $19.33 | 2025 | Hadlima |
| Phathom Pharmaceuticals, INC. | $18.74 | 2024 | Voquezna |
| Orphalan INC | $18.27 | 2025 | Cuvrior |
| Phadia US INC. | $13.64 | 2025 | Immunocap |
| Echosens North America, INC. | $3.99 | 2025 | Fibroscan |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Pointer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.